CRISPR/Cas9 gene editing is a powerful technology for functional genetic studies, especially in many rising model organisms such as the jewel wasp, Nasonia vitripennis. The ease of rearing and the availability of a complete genome makes the jewel wasp an important experimental system for elucidating the molecular mechanisms of different biological processes. For example, N. vitripennis has recently been used to unravel the epigenetic basis of the haplodiploid sex determination system1,2, the biology of B-chromosomes3,4,5,6, and the genetic basis for circadian and seasonal regulation7,8. Some of the features that make N. vitripennis amenable to work with include short generation time (~2 weeks at 25 °C), high reproduction rates, easy sex separation at the pupal stage, and the ability to diapause and store strains at 4 °C. The life cycle begins with female wasps parasitizing the pupae of the blowfly, Sarcophaga bullata. Through their ovipositor, females lay up to 50 eggs in the pupal case of the blowfly. Eggs develop into larvae that feed on the S. bullata pupa, continue to develop over the next several days, and then pupate, followed by adult eclosion and emergence from the host puparium9.
Molecular tools to perform functional genetic studies in N. vitripennis, such as RNA interference (RNAi)10 and CRISPR/Cas911,12, are available, but are limited, primarily due to difficulties in performing embryonic microinjections13. As N. vitripennis eggs require a pupal host for development, egg manipulation is very challenging. Pre-blastoderm stage embryos must be collected from the host blowfly pupae, quickly microinjected, and immediately transferred back to the host for development13. These steps require precision and specialized training to avoid damaging the microinjected embryos or the pupal hosts13. Moreover, the eggs are very small and fragile, especially after microinjections, with a very viscous cytoplasm causing a continuous clogging of the injecting needle13. These features make embryonic microinjections exceptionally challenging, requiring highly trained operators and specialized equipment that is absent in most N. vitripennis laboratories.
The optimization of alternative injection methods for the delivery of CRISPR reagents would contribute to the consolidation of N. vitripennis as a model organism. The manipulation of pupae and adults is less challenging than manipulating embryos and can be accomplished with a basic injection setup. Here, two protocols are described for injection of pupae and adults: one involving specialized equipment for injections, and the other involving the use of an aspirator tube assembly fitted with a glass capillary needle. The use of an aspirator tube is particularly suited for laboratories that do not have access to specialized equipment for embryo microinjections. Efficient injections of different developmental stages of N. vitripennis, including white or black pupae and adult wasps, are demonstrated. Wasps at the white pupal stage are particularly suited for RNAi-mediated knockdown experiments. Although RNAi in Nasonia was first described by Lynch and Desplan in 200610, there is no visual procedure available for how RNAi injections are performed. RNAi was recently used to discover the haploidizer gene of the B-chromosome PSR (Paternal Sex Ratio)3 and to study the involvement of the clock gene, period, in N. vitripennis biological rhythms7.
Black pupae and adult wasps can be used to induce CRISPR/Cas9 germline gene editing using ReMOT Control (Receptor-Mediated Ovary Transduction of Cargo) and BAPC (Branched Amphiphilic Peptide Capsules) protocols. These two ovary delivery methods have been recently described to be effective in Nasonia for generating germline mutations in the target gene, cinnabar7,12. Here, a simplified protocol is provided for injections including a visual procedure of a step-by-step methodology for both pupal and adult injections that can be utilized to generate functional genetics studies in Nasonia and likely in other parasitoid wasps, without requiring specialized equipment and bypassing embryonic microinjections.